Cantitate/Preț
Produs

Resistance to Immunotoxins in Cancer Therapy: Resistance to Targeted Anti-Cancer Therapeutics, cartea 6

Editat de Rama Shanker Verma, Benjamin Bonavida
en Limba Engleză Hardback – 27 iun 2015
This book will be a guide to understanding resistance against targeted therapeutic approaches for cancer using immunotoxins. It contains a detailed review of the history and development of targeted therapy. As well, it includes an in-depth description of the molecular and cellular mechanisms involved in cancer resistance and several novel methods to overcome resistance. Each chapter discusses different aspects of resistance and covers all the factors that may contribute to resistance in cancer cells. Finally, this volume highlights the recent findings and advances associated with tackling cancer resistance.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 71427 lei  6-8 săpt.
  Springer International Publishing – 17 oct 2016 71427 lei  6-8 săpt.
Hardback (1) 72119 lei  6-8 săpt.
  Springer International Publishing – 27 iun 2015 72119 lei  6-8 săpt.

Din seria Resistance to Targeted Anti-Cancer Therapeutics

Preț: 72119 lei

Preț vechi: 75915 lei
-5% Nou

Puncte Express: 1082

Preț estimativ în valută:
13801 14322$ 11536£

Carte tipărită la comandă

Livrare economică 15-29 martie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783319172743
ISBN-10: 3319172743
Pagini: 196
Ilustrații: XVI, 249 p. 22 illus., 19 illus. in color.
Dimensiuni: 155 x 235 x 22 mm
Greutate: 0.55 kg
Ediția:2015
Editura: Springer International Publishing
Colecția Springer
Seria Resistance to Targeted Anti-Cancer Therapeutics

Locul publicării:Cham, Switzerland

Public țintă

Research

Cuprins

1 Targeted Cancer Therapy: History and Development of Immunotoxins.-2 Immunotoxins, Resistance and Cancer Stem Cells: Future Perspective.-3 Factors that Determine Sensitivity and Resistances of Tumor Cells Towards Antibody-Targeted Protein Toxins.-4 Cell Signaling and Resistance to Immunotoxins.-5 Antibody-Drug Conjugates and Immunotoxins for the Treatment of Hematologic Neoplasms.-6 Challenges for Therapeutic Application of Pseudomonas Exotoxin-Based Immunotoxins .-7 Drug Resistance to Calicheamicin Conjugated Monoclonal Antibody Therapy .-8 Engineered Versions of Granzyme B and Angiogenin Overcome Intrinsic Resistance to Apoptosis Mediated by Human Cytolytic Fusion Proteins.-9 Therapeutic Impact of Immune Responses in Cancer.

Notă biografică

Rama Shanker Verma, Ph.D., is Professor, Department of Biotechnology, the Indian Institute of Technology. Professor Verma specializes in the development of novel immunotoxins for cancer therapies. He has published 76 scientific articles, five book chapters, and several conference abstracts. He is an Elected Fellow, the Association of Microbiologists of India an Elected Fellow, the Society for Applied Biotechnology. He received the award for Excellence in Medical Biotechnology from the Society for Applied Biotechnology.

Textul de pe ultima copertă

This volume is a guide to understanding resistance against targeted therapeutic approaches for cancer using immunotoxins. It contains a detailed review of the history and development of targeted therapy. As well, it includes an in-depth description of the molecular and cellular mechanisms involved in cancer resistance and several novel methods to overcome resistance. Each chapter discusses different aspects of resistance and covers all the factors that may contribute to resistance in cancer cells. Finally, this volume highlights the recent findings and advances associated with tackling cancer resistance.

Caracteristici

Identifies the mechanisms of resistance in immunotoxin-based therapies for cancer Explores available measures to overcome and prevent resistance in immunotoxin drugs Discusses an array of immune responses in cancer that impact therapeutic strategies